OncoGenex Announces Completion of Patient Enrollment in the Borealis-1(TM) Trial of OGX-427 in Metastatic Bladder Cancer
First of Six ORCA™ Trials to Reach Key Phase 2 Enrollment Milestone
BOTHELL, Wash. and VANCOUVER, British Columbia, July 16, 2013 /CNW/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that enrollment has been completed in Borealis-1™, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
Approximately 180 patients have been randomized into Borealis-1 at 55 clinical sites throughout North America and Europe. The three-arm trial randomized patients to receive gemcitabine, cisplatin, and OGX-427 at two dose-levels (600 mg or 1000 mg) vs. gemcitabine, cisplatin, and placebo. The primary endpoint of the trial is overall survival. Additional analyses will be conducted to evaluate benefit/risk of the two dosing levels using clinical benefit, safety and tolerability outcomes for each dose level.
"There are limited treatment options available for patients with metastatic bladder cancer and completion of enrollment in Borealis-1 brings us closer to validating novel therapies, such as OGX-427, that might overcome treatment resistance and extend survival," stated Cindy Jacobs MD, PhD, Executive Vice President and Chief Medical Officer of OncoGenex. "We expect data results to be available in the second-half of 2014, and if the trial is positive, we will initiate discussion with the Food and Drug Administration regarding next steps."
Borealis-1 is one of two ongoing clinical trials of OGX-427 in metastatic bladder cancer. The Borealis-2™ trial is an investigator-sponsored, randomized Phase 2 trial evaluating OGX-427 in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy. This trial is sponsored by the Hoosier O